Skip to main content

Cristina Hernández Pascual

Institutions of which they are part

Main researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Cristina Hernández Pascual

Institutions of which they are part

Main researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Intensificació FIS PI16/00541_Substitució Facultatiu Cristina Hernandez, Jornada complerta 40h

IP: Cristina Hernández Pascual
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 36000
Reference: PI16/00541
Duration: 01/01/2018 - 31/12/2019

Nuevas perspectivas en mediadores inflamatorios en la patogenia del edema macular diabético: implicaciones terapéuticas

IP: Cristina Hernández Pascual
Collaborators: Hugo Ramos Abellan, Patricia Bogdanov Baruj
Funding agency: Instituto de Salud Carlos III
Funding: 149132.5
Reference: PI19/01215
Duration: 01/01/2020 - 31/12/2022

Administración tópica ocular de inhibidores de DPP-4: una nueva estrategia terapéutica para la retinopatía diabética

IP: Cristina Hernández Pascual
Collaborators: J. Bruno Montoro Ronsano, Ana Boixadera Espax, José Raul Herance Camacho, Lorena Ramos Pérez
Funding agency: Instituto de Salud Carlos III
Funding: 119900
Reference: DTS18/00163
Duration: 01/01/2019 - 30/06/2021

Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of dementia

IP: Rafael Simó Canonge
Collaborators: Marina Jimenez Iglesias, Cristina Hernández Pascual, Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of d, Patricia Bogdanov Baruj, Andreea Ciudin Mihai, Ferran Casals Riera, Itziar Busquets Saez, Maddalen Zufiaurre Seijo, Enrique Franky Vargas, José Raul Herance Camacho, Ingrid Balcells Ortega, Marco Inzitari
Funding agency: EUROPEAN COMMISSION
Funding: 974782.7
Reference: RECOGNISED_H2020SC1BHC2019
Duration: 01/01/2020 - 31/12/2024

Related news

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Related professionals

Joaquim Vives Armengol

Joaquim Vives Armengol

Main researcher
Musculoskeletal Tissue Engineering
Read more
Nuria Casalé Cabanes

Nuria Casalé Cabanes

Predoctoral researcher
Infectious Diseases
Read more
Marcos Buj Vicente

Marcos Buj Vicente

Junior researcher
Shock, Organ Dysfunction and Resuscitation
Read more
Jaume Alijotas Reig

Jaume Alijotas Reig

Head of group
Systemic Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.